CandlesenseCandlesense
News/Companies/CNTA

CNTA News

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

CNTA

(NASDAQ:CNTA) BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Tuesday, September 9th at 4:50 PM ET.

September 3, 2025Conference
Read more →

Needham Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $35

CNTA

May 28, 2025
Read more →

Centessa Pharmaceuticals Q1 EPS $(0.20) Beats $(0.37) Estimate, Sales $15.00M

CNTA

May 14, 2025
Read more →

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

CNTA

May 8, 2025
Read more →

Chardan Capital Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $30

CNTA

May 8, 2025
Read more →

Piper Sandler Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $38

CNTA

March 31, 2025
Read more →

Guggenheim Reiterates Buy on Centessa Pharmaceuticals, Maintains $28 Price Target

CNTA

March 26, 2025
Read more →

Morgan Stanley Assumes Centessa Pharmaceuticals at Overweight, Maintains Price Target of $27

CNTA

March 7, 2025
Read more →

Centessa Pharmaceuticals Announces Poster Presentation Of Phase 1 Clinical Data For ORX750, A Novel Orexin Receptor 2 Agonist, At The AAN 2025 Annual Meeting

CNTA

March 6, 2025
Read more →

Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $28

CNTA

November 15, 2024
Read more →

FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate

CNTA

Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a proof-of-concept study evaluated SerpinPC in severe hemophilia A and B patients not on prophylaxis.

September 14, 2022
Read more →

Centessa Pharmaceuticals Announces Orphan Drug Designation Granted To SerpinPC For Treatment Of Hemophilia B

CNTA

September 14, 2022
Read more →

Centessa Pharmaceuticals To Discuss Non-Human Primate Pharmacokinetic And Safety Data For LB101 At Morgan Stanley 20th Annual Global Healthcare Conference

CNTA

September 12, 2022
Read more →